“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD
Open Access
- 1 February 2017
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 12, 487-494
Abstract
Many patients with chronic obstructive pulmonary disease (COPD) receive inhaled corticosteroids (ICSs) without a clear indication, and thus, the impact of ICS withdrawal on disease control is of great interest. DACCORD is a prospective, noninterventional 2-year study in the primary and secondary care throughout Germany. A subgroup of patients were taking ICS prior to entry – 1,022 patients continued to receive ICS for 2 years; physicians withdrew ICS on entry in 236 patients. Data from these two subgroups were analyzed to evaluate the impact of ICS withdrawal. Patients aged ≥40 years with COPD, initiating or changing COPD maintenance medication were recruited, excluding patients with asthma. Demographic and disease characteristics, prescribed COPD medication, COPD Assessment Test, exacerbations, and lung function were recorded. There were few differences in baseline characteristics; ICS withdrawn patients had shorter disease duration and better lung function, with 74.2% of ICS withdrawn patients not exacerbating, compared with 70.7% ICS-continued patients. During Year 1, exacerbation rates were 0.414 in the withdrawn group and 0.433 in the continued group. COPD Assessment Test total score improved from baseline in both groups. These data suggest that ICS withdrawal is possible with no increased risk of exacerbations in patients with COPD managed in the primary and secondary care.Keywords
This publication has 17 references indexed in Scilit:
- A year in the life of German patients with COPD: the DACCORD observational studyInternational Journal of Chronic Obstructive Pulmonary Disease, 2016
- Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPDNew England Journal of Medicine, 2016
- The ‘real-life’ COPD patient in Germany: The DACCORD studyRespiratory Medicine, 2016
- The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInternational Journal of Chronic Obstructive Pulmonary Disease, 2015
- Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPDNew England Journal of Medicine, 2014
- Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Respiratory Research, 2014
- Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCochrane Database of Systematic Reviews, 2014
- Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database of Systematic Reviews, 2014
- Inhaled corticosteroids for stable chronic obstructive pulmonary diseaseCochrane Database of Systematic Reviews, 2012
- Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodologyRespiratory Research, 2011